Twist Bioscience (TWST) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Twist Bioscience

NasdaqGS•Healthcare•Diagnostics & Research

$143.07+4.97(0.04%)Pre-market

Market Cap

$10.42B

P/S

24.1x

P/B

23.4x

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

How this company scores

AverageMetricSide Score: 44/100

Strongest: Growth (16/25); weakest: Cash & Earnings Quality (4/25).

Profitability9/25

Growth16/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality4/25

Strengths

Growing revenueInterest easily coveredConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 24.1x5y range 3.7x – 38.9x

Currently above its 20-quarter median.

P/B · 23.4x5y range 1.2x – 23.4x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $10.42B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $431.80M
Q. Revenue: $118.38M
TTM EBITDA: $-144.98M
TTM Op. Income: $-144.98M
Q. Op. Income: $-36.28M
TTM Net Income: $-136.72M
Q. Net Income: $-35.05M
EPS: $-0.56
Shares Out.: $62.40M

$431.80M in TTM revenue grew 19.2% YoY, reaching $118.38M last quarter. TTM EBITDA of $-144.98M and TTM operating income of $-144.98M show growth is flowing through to the bottom line. However, net income is negative at $136.72M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -30.6%
Op. Margin: -30.6%
Net Margin: -29.6%

Op. margin of -30.6% is up 0.7% YoY — cost efficiency is improving. Net margin at -29.6% Over the past year, operating margin is up 2% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 24.1x
P/B Ratio: 23.4x

P/S of 24.1x and P/B of 23.4x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $672.44M
Cash: $117.44M
Long-Term Debt: N/A
Book Value: $445.74M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.11M
TTM Free Cash Flow: $-93.12M
FCF Margin: -21.6%
FCF / Net Income: 0.7

TTM FCF of $-93.12M on $1.11M in operating cash flow. The FCF / Net Income ratio of 0.7x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 36% — an improving trend.